A Pilot Trial of a WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2018
At a glance
- Drugs Galinpepimut S (Primary) ; Montanide ISA-51; Sargramostim
- Indications Multiple myeloma
- Focus Pharmacodynamics
- 24 Jan 2018 According to a SELLAS Life Sciences Group media release, complete results from this study will be presented at European Society for Blood and Marrow Transplantation (EBMT) 44th Annual Meeting 2018.
- 10 Jun 2017 Biomarkers information updated
- 08 Feb 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.